Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Efficacy: To compare the single IV dose of fosaprepitant (in combination with ondansetron) to the ondansetron alone regimen with respect to the efficacy endpoint of Complete Response in the delayed phase (>24 to 120 hours) following the initiation of emetogenic chemotherapy in Cycle 1. Safety: To assess the safety and tolerability of the fosaprepitant regimen in pediatric subjects who are receiving emetogenic chemotherapy.
Critère d'inclusion
- Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy